On May 28, POZEN Inc (NASDAQ:POZN) Director Arthur S. Kirsch sold 10,000 shares of POZEN stock on the open market in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $8.38, for a total transaction of $83,800.00. Following the sale, the director now directly owns 26,000 shares in the company, valued at approximately $217,880. POZEN Inc. (NASDAQ:POZN) net profit margin is -49.10% and weekly performance is 2.26%. On last trading day company shares ended up $8.59. Analysts mean target price for the company is $9.00. POZEN Inc. (NASDAQ:POZN) distance from 50-day simple moving average (SMA50) is 1.83%.
On May 16, Biodel Inc. (NASDAQ:BIOD)’s shares were down 3.5% immediately after the company reported second quarter fiscal 2014 report. Overall, shares are down 6.9% since the company released second quarter results. The company reported a loss of 29 cents per share, narrower than the year-ago loss of 37 cents but wider than the Zacks Consensus Estimate of a loss of 26 cents per share. Biodel Inc (NASDAQ:BIOD) shares fell -1.39% in last trading session and ended the day on $2.13. Its return on assets is -49.70%. Biodel Inc (NASDAQ:BIOD) quarterly performance is -32.38%.
On May 20, 2014, Cardiome Pharma Corp. (NASDAQ:CRME) announced an agreement with AOP Orphan Pharmaceuticals AG, headquartered in Vienna, Austria, to commercialize AGGRASTAT® (tirofiban HCl) in selected European markets. AOP Orphan will be responsible for the commercialization of AGGRASTAT in the AOP Orphan countries. Under terms of the agreement, AOP Orphan has agreed to specific annual commercial goals for AGGRASTAT. Financial details of the agreement were not disclosed. CARDIOME PHARMA CORP (NASDAQ:CRME) shares moved down -2.99% in last trading session and was closed at $7.15, while trading in range of $6.82 – $7.34. CARDIOME PHARMA CORP (NASDAQ:CRME) year to date (YTD) performance is 14.77%.
On May 28, Aegis upgraded shares of Pernix Therapeutics Holdings Inc (NYSE:PTX) from a hold rating to a buy rating in a report issued on Tuesday, TheFlyOnTheWall.com reports. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) ended the last trading day at $7.11. Company weekly volatility is calculated as 5.57% and price to cash ratio as 4.80. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) showed a negative weekly performance of 10.40 %.
On May 27, Depomed, Inc. (NASDAQ:DEPO) announced that it will be presenting at the Jefferies 2014 Global Healthcare Conference in New York City. The presentation at the Jefferies conference is scheduled for 11:00 am ET (8:00 am PT) on Tuesday June 3, 2014. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website atwww.depomed.com. A recording of the webcast will be archived for 30 days on the company’s website. Depomed Inc (NASDAQ:DEPO) net profit margin is 36.10 % and weekly performance is 3.83%. On last trading day company shares ended up $11.93. Analysts mean target price for the company is $15.83. Depomed Inc (NASDAQ:DEPO) distance from 50-day simple moving average (SMA50) is -8.46%.